Next Article in Journal
Small RNA and mRNA Sequencing Reveal the Roles of microRNAs Involved in Pomegranate Female Sterility
Next Article in Special Issue
Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding
Previous Article in Journal
Endoplasmic Reticulum Stress Contributes to Indomethacin-Induced Glioma Apoptosis
Previous Article in Special Issue
Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis
Open AccessReview

Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection

Department of Oncology and Radiotherapy, Oulu University Hospital and MRC Oulu, 90220 Oulu, Finland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(2), 556; https://doi.org/10.3390/ijms21020556
Received: 19 December 2019 / Revised: 13 January 2020 / Accepted: 14 January 2020 / Published: 15 January 2020
(This article belongs to the Special Issue Cancer Immunotherapy Using Checkpoint Inhibitors: Future Directions)
Immune checkpoint inhibitor (ICI) therapies have become the most important medical therapies in many malignancies, such as melanoma, non-small-cell lung cancer, and urogenital cancers. However, due to generally low response rates of PD-(L)1 monotherapy, both PD-(L)1 combination therapies and novel therapeutics are under large-scale clinical evaluation. Thus far, clinical trials have rather suboptimally defined the patient population most likely to benefit from ICI therapy, and there is an unmet need for negative predictive markers aiming to reduce the number of non-responding patients in clinical practice. Furthermore, there is a strong need for basic tumor immunology research and innovative clinical trials to fully unleash the potential of ICI combinations for the benefit of patients. View Full-Text
Keywords: cancer immunotherapy; immune checkpoint inhibitors; predictive; biomarker; cost-effectiveness; immune-related adverse events; PD-L1 cancer immunotherapy; immune checkpoint inhibitors; predictive; biomarker; cost-effectiveness; immune-related adverse events; PD-L1
Show Figures

Figure 1

MDPI and ACS Style

Iivanainen, S.; Koivunen, J.P. Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. Int. J. Mol. Sci. 2020, 21, 556.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop